© Drug Hunter Inc. 2018-2023
Home > M3814
DNA-PK-selective kinase inhibitor
oral efficacy in xenograft radiation models
undisclosed screening and optimization
Mol. Cancer Ther., Mar. 27, 2020
Merck KGaA, Darmstadt, DE
M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year